Nymox Pharmaceutical Corp 6-K, filed Oct 22, 2025
Nymox Pharmaceutical Corp (NYMXF)
About this 6-K
Nymox Pharmaceutical Corp filed this 6-K on October 22, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October, 2025
Commission File Number: 001-12033
| Nymox Pharmaceutical Corporation |
| (Translation of registrant’s name into English) |
Bay & Deveaux Streets, Nassau, The Bahamas
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Nymox Pharmaceutical Corporation (the “Company”) reports that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025.
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 22, 2025
|
| NYMOX PHARMACEUTICAL CORPORATION |
| |
|
|
|
|
|
|
| By: | /s/ Paul Averback |
|
|
| Name: | Paul Averback |
|
|
| Title: | President and Chief Executive Officer |
|
| 3 |